Canadian Health Minister Clement Notes Progress At G8 Health Ministers Meeting

Canadian Health Minister Tony Clement was pleased with the outcome of discussions at the first-ever meeting of G8 Health Ministers in Moscow. Ministers renewed their international commitment to combat avian influenza and prevent and prepare for a possible human pandemic…

Read More

Abbott’s HUMIRA(R) (Adalimumab) Receives Positive Opinion From European Medicines Agency For The Treatment Of Ankylosing Spondylitis

Abbott today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), granted a positive opinion recommending approval of HUMIRA(R) (adalimumab) for the treatment of severe active ankylosing spondylitis. The…

Read More

Abbott’s New Tablet Formulation Of Kaletra(R) (Lopinavir/Ritonavir) Receives Positive Opinion From The European Medicines Agency

Abbott announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has issued a positive opinion recommending approval of a new, more convenient tablet formulation of its protease inhibitor…

Read More

Pharmacokinetic Data For Nastech’s Intranasal Parathyroid Hormone (PTH1-34) Demonstrated Similar Profile To Approved Injectable Product

Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) presents data today from a Phase I pharmacokinetic study of Parathyroid Hormone (PTH1-34) nasal spray demonstrating a similar pharmacokinetic profile to the approved subcutaneous product, Forteo(R) (teriparatide). The data are being presented at the…

Read More

Clinical Utility Of Two Novel Genes That Can Identify Patients At Higher Risk For Early Breast Cancer Recurrence

AviaraDx, Inc., formerly known as Arcturus Bioscience, Inc., a leader in molecular cancer profiling, announced today that a study, conducted in collaboration with Mayo Clinic, demonstrated the clinical utility of two novel genes that can identify patients at higher risk…

Read More

Positive Phase II Results With Orally Active GnRH Receptor Antagonist In Endometriosis – Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive results of its ‘proof of concept’, safety, efficacy and dose-finding Phase II clinical trial using its proprietary, orally-active small molecule Gonadotropin-Releasing Hormone (GnRH) receptor antagonist (NBI-56418). The 3-month data comes from a…

Read More